Can short-acting psychedelics solve the scalability problem in depression treatment?

Why is scalability the biggest challenge facing psychedelic treatments for depression in 2025?

Psychedelics have reignited hope for millions with treatment-resistant depression, but hope alone isn’t enough. As the clinical data rolls in—from ketamine analogs to psilocybin—regulators, providers, and payers are confronting a central question: can these therapies scale?

The latest buzz around bretisilocin, a short-acting psychedelic compound being acquired by AbbVie for up to USD 1.2 billion, has reenergized this debate. Developed by Gilgamesh Pharmaceuticals, bretisilocin is being positioned not just as another serotonergic agent, but as a potentially scalable solution to the operational and economic bottlenecks plaguing the psychedelic mental health revolution.

Traditional psychedelic therapies, including COMPASS Pathways’ psilocybin formulation and MAPS’ MDMA-assisted therapy, have demonstrated compelling efficacy in clinical trials. Yet their translation into clinical practice has been hampered by one issue: duration. Long session times, therapist oversight requirements, and infrastructure constraints make these therapies expensive, time-consuming, and difficult to integrate into standard care models.

Bretisilocin, by contrast, is designed to deliver robust antidepressant effects with a significantly shorter psychoactive experience. Its promise lies not just in what it does—but how quickly it does it, and how efficiently it could be administered at scale.

How does bretisilocin compare to psilocybin and ketamine analogs in terms of clinical practicality?

Gilgamesh’s bretisilocin is a next-generation 5-HT2A receptor agonist and 5-HT releaser—built for speed and efficiency. In a recent Phase 2a trial, a single 10mg dose delivered a 21.6-point reduction in MADRS score at Day 14. Crucially, it achieved this without serious adverse events and with a short psychoactive window, setting it apart from conventional psychedelics.

Psilocybin, by contrast, requires extensive in-clinic supervision. Trials like those led by COMPASS Pathways typically involve a 6–8 hour psychoactive period, requiring dedicated rooms, multiple trained therapists, and post-session recovery. This burden has raised red flags for insurers and hospital systems, especially in geographies where psychiatric infrastructure is already under pressure.

Ketamine—specifically Spravato (esketamine)—was supposed to solve this, but its adoption has been patchy. While fast-acting and approved, Spravato requires Risk Evaluation and Mitigation Strategy (REMS) protocols in the U.S., with patients observed for two hours post-dose in certified treatment centers. Its side effect profile, including dissociation and blood pressure spikes, has also raised questions about long-term safety and positioning.

In this context, bretisilocin may represent the “Goldilocks” model—short-acting enough to avoid logistical nightmares, effective enough to rival deeper-acting psychedelics, and safer than existing dissociative agents. If late-stage data holds, it could unlock a new framework for scalable psychedelic care.

What barriers are limiting real-world deployment of current psychedelic treatments?

Despite increasing regulatory openness, the practical deployment of psychedelics in clinical settings has hit multiple roadblocks.

First, infrastructure. Traditional psychiatric clinics are not equipped for multi-hour psychedelic sessions. Reimbursement models don’t support day-long therapy, and many facilities lack private rooms or trained facilitators.

Second, regulatory oversight. Compounds like MDMA and psilocybin are still Schedule I in many jurisdictions. Even when approved for medical use, strict monitoring requirements can make implementation costly and administratively complex.

Third, payer skepticism. Insurance companies remain wary of high upfront costs and uncertain long-term outcomes. Ketamine’s variable results and the patchy adoption of Spravato have added to this caution. While breakthrough therapy designations help, widespread payer adoption often hinges on cost-effectiveness studies that few psychedelic trials have completed.

Lastly, public perception. Although stigma is declining, concerns around misuse, long-term safety, and cultural acceptability continue to shadow the field.

Bretisilocin could mitigate these challenges by eliminating the need for day-long sessions and minimizing clinical burden. A shorter administration window not only lowers costs but also reduces the risk of adverse events, making it more appealing to both regulators and payers.

How are biotech investors and institutional stakeholders reacting to the short-acting psychedelic model?

The USD 1.2 billion deal between AbbVie and Gilgamesh Pharmaceuticals underscores growing institutional appetite for psychedelic therapeutics that are clinically effective and commercially scalable.

Analysts see bretisilocin’s short duration and positive tolerability profile as ticking both boxes. Unlike boutique biotechs chasing niche applications, AbbVie brings global regulatory expertise, commercial scale, and psychiatric infrastructure to accelerate development.

Investor sentiment around traditional psychedelics has been more mixed. COMPASS Pathways (NASDAQ: CMPS) has seen its share price fluctuate significantly as trial results, reimbursement uncertainty, and infrastructure costs spook investors. MAPS’ nonprofit status has limited capital flow, while companies like MindMed and Atai have struggled to move beyond proof-of-concept.

The Gilgamesh model—develop first, validate in trials, spin out non-core programs, and monetize via big pharma licensing—may become a playbook for other psychedelic startups seeking non-dilutive exits without full-scale commercialization burdens.

What are the implications for clinical trial design and regulatory acceleration in the short-acting psychedelic space?

Short-acting psychedelics may not only be easier to deploy but also easier to study. Bretisilocin’s short duration simplifies blinding and reduces dropout risk, two major concerns in psychedelic trials. It also enables more feasible outpatient models, where participants can be safely discharged within hours, rather than monitored all day.

These design efficiencies could translate into faster trial timelines and clearer regulatory pathways. Analysts expect AbbVie to seek Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) as it moves into Phase 2b or Phase 3 studies.

Compared to psilocybin trials—which often struggle with standardizing therapeutic protocols, session length, and participant expectations—bretisilocin’s more pharmacological, less behavioral model may make regulatory review more predictable. This aligns with broader FDA trends favoring measurable endpoints, real-world safety profiles, and scalable models of care.

What’s next for Gilgamesh Pharmaceuticals and the broader field of mental health innovation?

The transaction allows Gilgamesh to spin out its remaining programs—including blixeprodil (an oral NMDA receptor antagonist), cardio-safe ibogaine analogs, and M1/M4 agonist therapies—into a new entity, Gilgamesh Pharma Inc. The option-to-license framework with AbbVie remains intact, giving both parties flexibility to collaborate on additional compounds in the future.

For the broader psychedelics ecosystem, this deal represents an inflection point. The era of long, resource-intensive psychedelic therapy may be giving way to a new model—driven by chemistry, designed for clinics, and funded by pharma.

If bretisilocin’s promise holds, it could catalyze a new generation of psychiatric treatments that bridge the gap between innovation and implementation. And in doing so, it may redefine what “scalable” actually means in mental health care.